Twist Bioscience Reports Fiscal Fourth Quarter and Full Year Fiscal 2022 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Dow tick higher as investors weigh Mideast negotiations
- Oil falls 4% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
- Sanuwave cuts Q2 2026 revenue guidance amid Ultramist sales pressure
Twist Bioscience Corporation (TWST) Tops Q4 EPS by 36c, Offers Guidance
November 18, 2022 7:33 AM ESTTwist Bioscience Corporation (NASDAQ: TWST) reported Q4 EPS of ($0.91), $0.36 better than the analyst estimate of ($1.27). Revenue for the quarter came in at $57.3 million versus the consensus estimate of $56.78 million.
GUIDANCE:
Twist Bioscience Corporation sees Q1 2023 revenue of $54 million, versus the... More
